Selected Reads

Smartkarma

Equity Bottom-Up

NVAX Summary We believe Novavax (NVAX), a Covid vaccine manufacturer, is overvalued with &gt;50% downside. As a poorly managed, late and subscale player in a declining market, we believe that there is...<a target="_blank" href="https://www.valueinvestorsclub.com/idea/NOVAVAX_INC/5307307503">Read the article on Value Investor Club »</a>

United States

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00